AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020

Rhea-AI Summary

Applied Genetic Technologies Corporation (AGTC), a biotechnology firm focused on gene therapies for rare diseases, announced that CEO Sue Washer will present at the BMO Capital Markets 2020 Healthcare Conference on June 23 at 10:30 am ET. The event can be streamed live on the company's website, with a replay available afterward. Earlier this year, AGTC reported promising interim data from its clinical trials for X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) therapies, demonstrating the company's commitment to addressing significant unmet medical needs.

GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 at 10:30 am ET.

A live audio webcast of the presentation will be available by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the company's website following the event.

In January 2020, AGTC announced positive interim six-month data from its ongoing Phase 1/2 clinical program in XLRP and encouraging interim data from the dose-escalation cohorts of its ongoing Phase 1/2 clinical programs in patients with ACHM due to mutations in the ACHM CNGB3 or ACHM CNGA3 genes.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. Initially focusing on ophthalmology, our goal is to preserve or, hopefully, be able to improve vision in some cases. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Our pre-clinical programs build on our industry leading AAV manufacturing technology and expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

When is AGTC's presentation at the BMO Capital Markets Healthcare Conference?

AGTC's presentation is scheduled for June 23, 2020, at 10:30 am ET.

How can I watch AGTC's presentation live?

The live audio webcast of AGTC's presentation can be accessed via their official website.

What updates did AGTC provide on their clinical trials in 2020?

In January 2020, AGTC announced positive interim data from its Phase 1/2 clinical trials for XLRP and encouraging data for ACHM.

What is the focus of AGTC's gene therapies?

AGTC focuses on developing genetic therapies for rare ophthalmic, otologic, and CNS diseases.

What company is represented by the ticker symbol AGTC?

The ticker symbol AGTC represents Applied Genetic Technologies Corporation.